Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Computational modeling identifies protective mechanisms of estrogen and testosterone against atrial fibrosis.

American journal of physiology. Heart and circulatory physiology·2026

Same author

Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.

ACS pharmacology & translational science·2026

Same author

Nitrogen-Doped Graphene Quantum Dots Conjugated to Leucettinib-21 Rescue Differentiating Zebrafish Purkinje Cells by Inhibiting Dyrk1A Kinase.

ACS applied nano materials·2026

Same author

Semaglutide Reverses Ectopic Lipid Accumulation, Impaired Myocardial Perfusion Reserve, and Diastolic Dysfunction in a Mouse Model of Cardiometabolic Heart Disease.

JACC. Basic to translational science·2026

Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026

Same author

Cerebrospinal Fluid Metagenomic Next-Generation Sequencing in Pediatric Central Nervous System Infection: Clinical Experience and Diagnostic Stewardship Strategies.

Open forum infectious diseases·2026

Search research articles

Related Experiment Video

Updated: May 5, 2026

Creating a Structurally Realistic Finite Element Geometric Model of a Cardiomyocyte to Study the Role of Cellular Architecture in Cardiomyocyte Systems Biology

Creating a Structurally Realistic Finite Element Geometric Model of a Cardiomyocyte to Study the Role of Cellular Architecture in Cardiomyocyte Systems Biology

Published on: April 18, 2018

Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury.

Bryce C Murillo¹, Alexander Young², Kaitlyn L Wintruba³

¹Department of Pharmacology University of Virginia, Charlottesville VA, USA.

Biorxiv : the Preprint Server for Biology

|September 3, 2025

Summary

Inhibiting DYRK1A promotes heart regeneration after myocardial infarction by enabling cardiomyocyte cell cycle re-entry. This approach improves heart function and offers a new therapeutic strategy for cardiac repair.

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

Related Experiment Videos

Last Updated: May 5, 2026

Creating a Structurally Realistic Finite Element Geometric Model of a Cardiomyocyte to Study the Role of Cellular Architecture in Cardiomyocyte Systems Biology

Creating a Structurally Realistic Finite Element Geometric Model of a Cardiomyocyte to Study the Role of Cellular Architecture in Cardiomyocyte Systems Biology

Published on: April 18, 2018

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

Area of Science:

Cardiovascular Biology
Molecular Cardiology
Regenerative Medicine

Background:

Adult mammalian heart regeneration is limited by cardiomyocyte proliferation.
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) regulates cell quiescence, but its precise role in cardiomyocytes is unclear.
Pharmacological DYRK1A inhibition has shown potential in promoting cardiomyocyte cell cycle re-entry after myocardial infarction (MI).

Purpose of the Study:

To elucidate the mechanisms by which DYRK1A inhibition promotes cardiomyocyte cell cycle re-entry.
To validate the therapeutic potential of DYRK1A inhibition in a preclinical model of cardiac injury.

Main Methods:

Development of a computational network model of DYRK1A-mediated cell cycle regulation.
Testing selective DYRK1A inhibitors in neonatal rat cardiomyocytes (NRCMs).
Integration of network model with bulk RNA-sequencing data and in vivo studies using a mouse model of ischemia/reperfusion (I/R) MI.

Main Results:

The computational model predicted DYRK1A inhibition's role in cardiomyocyte cell cycle re-entry.
DYRK1A inhibitors robustly induced cell cycle activity in NRCMs.
E2F1 was identified as a key transcriptional driver of cell cycle gene expression.
Pharmacological and post-developmental DYRK1A inhibition improved heart function and increased cardiomyocyte cycling post-I/R MI.

Conclusions:

DYRK1A inhibition is a viable strategy to enhance cardiomyocyte proliferation and cardiac repair.
The findings highlight E2F1 as a critical mediator in DYRK1A-regulated cell cycle progression.
Small molecule inhibition of DYRK1A offers a promising therapeutic avenue for treating myocardial infarction.